Beyond Immunotherapy: New RCC Hope With TPST-1120 and Nivolumab Combo
February 4th 2024In an interview with Targeted Oncology, Bruno Bastos, MD, discussed how TPST-1120 can help address limited treatment options for patients with advanced renal cell carcinoma beyond immunotherapy and anti-VEGF tyrosine kinase inhibitors.
Read More